American Society of Hirudotherapy

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022) · Perfusion · n=1232

Review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE LowSystematic reviewBivalirudin: drug studies

Study Profile

Design
systematic review and meta-analysis of 12 retrospective cohort studies through April 2022 (PubMed, Embase, Cochrane Library)
Pooled sample (n; included studies may overlap)
1232
Scope
Bivalirudin anticoagulation for ECMO (n=497 across pooled cohorts)
Main result
No significant difference in mortality (RR 0.95, 95% CI 0.79-1.13, p=0.546) or thrombotic events (RR 0.78, 95% CI 0.45-1.35); bivalirudin significantly reduced bleeding events (RR 0.48, 95% CI 0.25-0.95, p=0.035)

Key Findings

  • Largest contemporary pooled dataset (n=1,232) on ECMO anticoagulation choice
  • Equivalent mortality between bivalirudin and heparin
  • Equivalent thrombotic event rates
  • Bivalirudin associated with reduced bleeding complications (52% relative reduction)
  • Highlights need for prospective RCTs

Limitations

  • All included studies were retrospective observational
  • Significant clinical heterogeneity across centers
  • Publication bias likely
  • Patient selection bias - sicker patients more likely to receive bivalirudin
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Huang 2022 is a foundational evidence synthesis for ECMO anticoagulation choice. For ASH, the meta-analysis demonstrates how the synthetic hirudin-derivative pathway operates under retrospective observational evidence with bleeding-reduction signal but no mortality benefit. This evidence base is structurally distinct from the device-leech K040187 US practice and serves as a reference for the broader hirudin-derived anticoagulant landscape.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.